Kenvue Inc. (NYSE:KVUE) Holdings Lowered by Baugh & Associates LLC

Baugh & Associates LLC trimmed its stake in shares of Kenvue Inc. (NYSE:KVUE) by 1.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,534 shares of the company’s stock after selling 790 shares during the quarter. Kenvue comprises 0.9% of Baugh & Associates LLC’s holdings, making the stock its 29th biggest position. Baugh & Associates LLC’s holdings in Kenvue were worth $1,680,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Leo Wealth LLC raised its position in shares of Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after buying an additional 481 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its holdings in shares of Kenvue by 6.2% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock worth $194,000 after purchasing an additional 492 shares in the last quarter. Wolff Wiese Magana LLC raised its holdings in shares of Kenvue by 0.7% in the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after purchasing an additional 501 shares in the last quarter. Marathon Capital Management raised its holdings in shares of Kenvue by 0.3% in the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after purchasing an additional 514 shares in the last quarter. Finally, Manchester Capital Management LLC raised its holdings in shares of Kenvue by 80.8% in the 1st quarter. Manchester Capital Management LLC now owns 1,186 shares of the company’s stock worth $25,000 after purchasing an additional 530 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

Shares of KVUE opened at $22.50 on Thursday. The company’s 50 day moving average price is $22.59 and its 200 day moving average price is $20.49. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $23.57. The company has a market capitalization of $43.09 billion, a PE ratio of 38.79, a PEG ratio of 3.01 and a beta of 1.36. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.68 and a current ratio of 0.99.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.04. The firm had revenue of $4 billion for the quarter, compared to the consensus estimate of $3.93 billion. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The firm’s revenue was down .3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.32 earnings per share. Research analysts expect that Kenvue Inc. will post 1.08 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th will be given a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.64%. The ex-dividend date is Wednesday, November 13th. Kenvue’s dividend payout ratio is 141.38%.

Wall Street Analyst Weigh In

A number of research firms recently commented on KVUE. Royal Bank of Canada downgraded shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price on the stock. in a report on Tuesday, September 24th. UBS Group boosted their target price on shares of Kenvue from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Bank of America boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. JPMorgan Chase & Co. boosted their price target on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Finally, Piper Sandler boosted their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a report on Monday, September 23rd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.